{"id":2392,"date":"2014-09-24T16:25:00","date_gmt":"2014-09-24T20:25:00","guid":{"rendered":"https:\/\/www.med.unc.edu\/htcenter\/fda-approves-baxters-rixubis-for-treatment-of-children-with-hemophilia-b\/"},"modified":"2022-09-28T15:29:12","modified_gmt":"2022-09-28T19:29:12","slug":"fda-approves-baxters-rixubis-for-treatment-of-children-with-hemophilia-b","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/htcenter\/fda-approves-baxters-rixubis-for-treatment-of-children-with-hemophilia-b\/","title":{"rendered":"FDA approves Baxter&#8217;s RIXUBIS for treatment of children with hemophilia B"},"content":{"rendered":"<p class=\"lead\">On September 12, 2014, the United States Food and Drug Administration (FDA) approved Baxter International Inc.&#8217;s RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B.<\/p>\n<div>\n<p>RIXUBIS was the first recombinant factor IX or rFIX approved for routine prophylaxis and control of bleeding episodes in the U.S. for adults living with this chronic condition.<\/p>\n<p>The approval is based on the results of a study investigating the efficacy and safety of RIXUBIS among 23 previously treated male patients less than 12 years of age with severe or moderately severe hemophilia B. Baxter&#8217;s application for marketing approval for RIXUBIS for adults and pediatric patients is currently under review in the European Union, with a regulatory decision expected later this year. Also, the treatment recently gained regulatory approval in Australia.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>On September 12, 2014, the United States Food and Drug Administration (FDA) approved Baxter International Inc.&#8217;s RIXUBIS for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B.<\/p>\n","protected":false},"author":38607,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-2392","post","type-post","status-publish","format-standard","hentry","category-news","odd"],"acf":[],"featured_image":false,"featured_image_medium":false,"featured_image_medium_large":false,"featured_image_large":false,"featured_image_thumbnail":false,"featured_image_alt":false,"category_details":[{"name":"HTC News","link":"https:\/\/www.med.unc.edu\/htcenter\/category\/news\/"}],"tag_details":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/posts\/2392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/users\/38607"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/comments?post=2392"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/posts\/2392\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/media?parent=2392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/categories?post=2392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/tags?post=2392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}